Long-term renal function in liver transplant recipients after conversion from calcineurin inhibitors to mTOR inhibitors

Annals of Transplantation

Volumn 20, Issue , 2015, Pages 707-713

  Hüsing, Anna ^a   Schmidt, Martina ^a   Beckebaum, Susanne ^a   Cicinnati, Vito R ^a   Koch, Raphael ^b   Thölking, Gerold ^a   Stella, Jaqueline ^a   Heinzow, Hauke ^a   Schmidt, Hartmut H ^a   Kabar, Iyad ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Calcineurin; Immunosuppression; Liver transplantation; Renal insufficiency; TOR serine threonine kinases

Indexed keywords

CALCINEURIN INHIBITOR; CHOLESTEROL; CYCLOSPORIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL; IMMUNOSUPPRESSIVE AGENT; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; IMMUNE DEFICIENCY; KIDNEY FUNCTION; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PANCYTOPENIA; PROTEINURIA; RETROSPECTIVE STUDY; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; COHORT ANALYSIS; COMPARATIVE STUDY; FOLLOW UP; GERMANY; GRAFT SURVIVAL; HISTOCOMPATIBILITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; PROCEDURES; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ADULT; CALCINEURIN INHIBITORS; COHORT STUDIES; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; GERMANY; GRAFT REJECTION; GRAFT SURVIVAL; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LINEAR MODELS; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SIROLIMUS; SURVIVAL RATE; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 84949194850     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.895320     Document Type: Article

References (21)

1. Starzl TE, Iwatsuki S, Van Thiel DH et al: Evolution of liver transplantation. Hepatology (Baltimore, Md), 1982; 2: 614-36
2. Londono MC, Rimola A, O'Grady J, Sanchez-Fueyo A: Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. J Hepatol, 2013; 59: 872-79
3. Calne RY: Immunosuppression in liver transplantation. N Engl J Med, 1994; 331: 1154-55
4. Gotthardt DN, Bruns H, Weiss KH, Schemmer P: Current strategies for immunosuppression following liver transplantation. Langenbecks Arch Surg, 2014; 399(8): 981-88
5. Ojo AO, Held PJ, Port FK et al: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med, 2003; 349: 931-40
6. Sirivatanauksorn Y, Parakonthun T, Premasathian N et al: Renal dysfunction after orthotopic liver transplantation. Transplant Proc, 2014; 46: 818-21
7. Watt KD, Pedersen RA, Kremers WK et al: Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow- up study. Am J Transplant, 2010; 10: 1420-27
8. Beckebaum S, Cicinnati VR, Radtke A, Kabar I: Calcineurin inhibitors in liver transplantation - still champions or threatened by serious competitors? Liver Int, 2013; 33: 656-65
9. Fischer L, Klempnauer J, Beckebaum S et al: A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation - PROTECT. Am J Transplant, 2012; 12: 1855-65
10. Perez T, Segovia R, Castro L et al: Conversion to everolimus in liver transplant patients with renal dysfunction. Transplant Proc, 2011; 43: 2307-10
11. Abdelmalek MF, Humar A, Stickel F et al: Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant, 2012; 12: 694-705
12. Saliba F, De Simone P, Nevens F et al: Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant, 2013; 13: 1734-45
13. Levey AS, Stevens LA, Schmid CH et al: A new equation to estimate glomerular filtration rate. Ann Intern Med, 2009; 150: 604-12
14. Verbeke G, Molenberghs G: Linear mixed models for longitudinal data. Springer Series in Statistics, Springer-Verlag, Berlin-Heidelberg-New York, 2000
15. Beckebaum S, Cicinnati VR: Conversion to combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy for renal dysfunction in liver transplant patients: never too late? Dig Dis Sci, 2011; 56: 4-6
16. Farkas SA, Schnitzbauer AA, Kirchner G et al: Calcineurin inhibitor minimization protocols in liver transplantation. Transplant Int, 2009; 22: 49-60
17. Cicinnati VR, Yu Z, Klein CG et al: Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients - assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther, 2007; 26: 1195-208
18. Kornberg A, Kupper B, Hommann M, Scheele J: Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol, 2005; 5: 141-46
19. Campbell KH, O'Hare AM: Kidney disease in the elderly: update on recent literature. Curr Opin Nephrol Hypertens, 2008; 17(3): 298-303
20. O'Hare AM, Choi AI, Bertenthal D et al: Age affects outcomes in chronic kidney disease. J Am Soc Nephrol, 2007; 18: 2758-65
21. Perazella MA: Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol, 2009; 4: 1275-83